In cohort 2, 49 patients received 1 mg/kg nivolumab plus ipilimumab, which is an anti-cytotoxic T lymphocyte-associated protein 4 (CTLA4) monoclonal antibody, at a dosage of 3 mg/kg every three weeks; 24% of the tumor samples were PD-L1 positive. The gene discussed is CTLA4; the disease is neoplasm.